Cancer Biomarkers Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 25.0 billion
Estimated Base Value
2035 Forecast
US$ 64.8 billion
Projected Market Value
CAGR 2026–2035
10.0%
Compound Annual Growth
Largest Segment
Protein Biomarkers
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
Asia Pacific
Fastest Growing Region
Latin America
Top Country
United States
By Market Share
Largest market
Key Players
Exact Sciences
Emerging Players
Lucence, C2i Genomics
Cancer Biomarkers Market Overview
The Cancer Biomarkers Market involves the development and commercialization of biological molecules and associated assays used in oncology. These biomarkers help detect cancer, assess disease progression, predict treatment response, and monitor recurrence. This market is crucial for advancing precision medicine within the pharmaceutical industry, enabling targeted therapies and personalized treatment regimens. It encompasses a variety of diagnostic tests, kits, and services that utilize genomic, proteomic, and metabolomic markers found in bodily fluids or tissues. Applications include early detection, risk stratification, companion diagnostics for specific drugs, and post-treatment surveillance, aiming to improve patient outcomes through tailored medical interventions.
The Cancer Biomarkers Market is estimated at $25.0 Bn in 2025 and is forecast to reach $64.8 Bn in 2035, growing at a CAGR of 10.0% from 2025 to 2035. Demand is driven by the rising global incidence of cancer and the increasing need for personalized oncology treatments. Technological advancements in biomarker discovery and analysis, alongside increased R&D spending in cancer diagnostics, also propel market expansion. However, high development and validation costs, stringent regulatory pathways, and reimbursement challenges act as restraints on market growth.
The market is segmented by Type (Protein Biomarkers, Genetic & Genomic Biomarkers, Epigenetic Biomarkers, Circulating Tumor Cell Biomarkers, Circulating Tumor DNA Biomarkers, Metabolomic Biomarkers, Glycosylation Biomarkers), Application (Diagnosis, Prognosis, Theragnostics & Treatment Selection, Disease Monitoring, Drug Discovery & Development), Technology (Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, Mass Spectrometry, Flow Cytometry, Microarrays, Enzyme-Linked Immunosorbent Assay), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia & Lymphoma, Ovarian Cancer, Others), End-User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations), and Source (Tissue Biopsies, Blood Samples, Other Body Fluid Samples, Cell Lines, Animal Models). It is served across Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Leading companies include Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, Qiagen, Myriad Genetics, Veracyte, NeoGenomics, Adaptive Biotechnologies, Freenome, and Personalis. The full report provides a comprehensive analysis of these segments and regional dynamics.
Market Definition & Overview
The Cancer Biomarkers Market encompasses the development, manufacturing, and commercialization of biological molecules and associated assays used to detect the presence of cancer, assess disease progression, predict treatment response, and monitor recurrence. This market is pivotal for advancing precision medicine within the pharmaceutical industry, enabling highly targeted therapies and personalized treatment regimens. It includes a range of diagnostic tests, kits, and services leveraging genomic, proteomic, metabolomic, and other molecular markers found in various bodily fluids or tissues. Key applications span early detection, risk stratification, companion diagnostics for specific pharmaceutical drugs, and post-treatment surveillance, driving innovation in oncology and improving patient outcomes through tailored medical interventions.
Scope
- Global market coverage across all major regions
- Analysis of diagnostic, prognostic, and predictive biomarker applications in oncology
- Market sizing and forecast from 2025 to 2035
Inclusions
- Biomarker assays and kits for cancer diagnosis, prognosis, and monitoring
- Companion diagnostics (CDx) for guiding targeted cancer therapies
- Technologies for genomic, proteomic, and epigenomic biomarker analysis
- Services for biomarker discovery, validation, and commercialization support
- Research tools and reagents specifically for cancer biomarker studies
- In vitro diagnostic (IVD) devices leveraging cancer-specific molecular markers
Exclusions
- General medical diagnostic devices not utilizing specific cancer biomarkers
- Therapeutic pharmaceutical drugs themselves, independent of biomarker guidance
- Biomarkers unrelated to cancer conditions or their treatment
- Basic research consumables and equipment not specific to biomarker analysis
- Surgical instruments or general laboratory automation platforms
- Direct patient care services not involving biomarker testing
Market Size Forecast
Executive Summary
• The Cancer Biomarkers market is valued at $25.0 Bn in 2025 and is forecast to reach $64.8 Bn by 2035, reflecting a robust CAGR of 10.0% as demand accelerates across every major segment and region over the ten-year outlook.
• Protein Biomarkers leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Strategic collaborations between diagnostic developers and pharmaceutical giants are intensifying, signaling a robust trend toward vertically integrated precision oncology solutions and influencing the competitive landscape across key global markets.
• The accelerated integration of next-generation sequencing and liquid biopsy technologies, alongside evolving regulatory frameworks, is fundamentally reshaping biomarker discovery and validation pathways, particularly in advanced cancer diagnostics.
• Expanding clinical utility beyond initial diagnosis to include therapy selection and recurrence monitoring represents a significant growth catalyst, pushing biomarker integration deeper into personalized cancer treatment paradigms worldwide.
• Differentiated market penetration across specific cancer types and varying regional reimbursement policies necessitate tailored strategic approaches for sustained growth, with emerging economies poised for substantial, albeit nascent, adoption.
• Significant venture capital investment continues to fuel innovation in AI-driven biomarker platforms and data analytics, crucial for scaling personalized medicine and optimizing diagnostic assay development pipelines globally.
• The paradigm shift towards multi-omic profiling and companion diagnostics is driving demand for comprehensive biomarker panels, compelling stakeholders to prioritize interoperability and data standardization for future market leadership.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The cancer biomarkers market was valued at $25.0 billion in the base year, indicating its substantial foundational size within the precision medicine industry.
Robust Growth Outlook
The market is projected to achieve a valuation of $64.8 billion by the forecast year, demonstrating significant future expansion.
Double-Digit Expansion
A remarkable compound annual growth rate (CAGR) of 10.0% is anticipated for the cancer biomarkers market, signifying rapid growth potential.
Market Projection
From its $25.0 billion base year value, the cancer biomarkers market is set for a substantial increase to $64.8 billion by the forecast year, driven by diagnostic advancements.
Precision Medicine Driver
Cancer biomarkers are a critical component driving the expansion of precision medicine in oncology, enabling personalized therapeutic and diagnostic approaches.
Liquid Biopsy Trend
The increasing integration and adoption of liquid biopsies represent a notable trend, offering less invasive and more dynamic insights into cancer progression and treatment response.
Market Dynamics
Market Trends
- Liquid biopsy adoption is rising for non-invasive cancer detection.
- AI and machine learning are increasingly used for biomarker discovery.
- Multi-omics data integration offers comprehensive patient profiling.
- Focus on companion diagnostics for targeted cancer therapies is growing.
Growth Drivers
- Rising global cancer incidence fuels demand for biomarkers.
- Growing need for personalized oncology treatments drives market.
- Technological advancements enhance biomarker discovery and analysis.
- Increased R&D spending in cancer diagnostics propels growth.
Restraints
- High development and validation costs limit market growth.
- Stringent regulatory pathways delay biomarker approval and adoption.
- Lack of standardization impacts test accuracy and clinical utility.
- Reimbursement challenges hinder broad market accessibility.
Opportunities
- Early cancer detection and risk assessment offer vast potential.
- Developing biomarkers for immunotherapy response prediction is key.
- Untapped emerging markets present significant growth avenues.
- Strategic partnerships can integrate biomarkers into drug development.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Protein BiomarkersGenetic & Genomic BiomarkersEpigenetic BiomarkersCirculating Tumor Cell BiomarkersCirculating Tumor DNA BiomarkersMetabolomic BiomarkersGlycosylation Biomarkers |
| By Application | DiagnosisPrognosisTheragnostics & Treatment SelectionDisease MonitoringDrug Discovery & Development |
| By Technology | Next Generation SequencingPolymerase Chain ReactionImmunohistochemistryMass SpectrometryFlow CytometryMicroarraysEnzyme-Linked Immunosorbent Assay |
| By Cancer Type | Lung CancerBreast CancerColorectal CancerProstate CancerMelanomaLeukemia & LymphomaOvarian CancerOthers |
| By End-User | Hospitals & ClinicsDiagnostic LaboratoriesAcademic & Research InstitutesPharmaceutical & Biotechnology CompaniesContract Research Organizations |
| By Source | Tissue BiopsiesBlood SamplesOther Body Fluid SamplesCell LinesAnimal Models |
Regional Analysis
- North America leads the cancer biomarkers market due to its robust R&D infrastructure, high adoption of advanced diagnostics, and significant investment in precision medicine. A large patient pool and early access to innovative therapies further solidify its dominant position.
- The Asia-Pacific region is the fastest-growing market, driven by increasing healthcare expenditure, rising cancer incidence, and improving diagnostic facilities. Growing awareness of personalized medicine and supportive government initiatives further fuel its expansion.
- Europe is seeing a noteworthy trend with increasing adoption of liquid biopsies for cancer detection and monitoring. This non-invasive method offers significant advantages for early diagnosis and personalized treatment tracking, gaining traction across the region as a less intrusive patient management approach.
| Asia PacificXX.X% | North AmericaXX.X% | EuropeXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A significant market segment characterized by advanced R&D capabilities, high adoption rates of personalized medicine, and a strong presence of leading pharmaceutical and biotech companies.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- An emerging market experiencing rapid growth due to increasing healthcare expenditure, improving access to advanced diagnostics, and a growing awareness of precision oncology benefits.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region maintains a substantial market share, supported by robust healthcare spending, established research institutions, and a rising focus on early cancer diagnosis and targeted therapies.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This region holds the largest market share, driven by increasing cancer incidence, improving healthcare infrastructure, and growing government initiatives for precision medicine across key economies like China and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- This developing market shows promising growth potential, fueled by rising investments in healthcare infrastructure, increasing prevalence of cancer, and efforts to modernize diagnostic capabilities in select countries.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads the global cancer biomarkers market due to extensive R&D investments, a strong presence of pharmaceutical and biotech companies, and high adoption rates of advanced diagnostic technologies for precision oncology. Its robust regulatory framework and high healthcare spending further fuel market growth. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As the largest economy in Latin America, Brazil offers a substantial patient pool and increasing healthcare expenditure, driving demand for precision oncology and advanced cancer biomarker testing. Government initiatives to improve cancer care also contribute to its market growth. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany boasts a leading pharmaceutical sector, significant R&D spending, and an advanced healthcare system, making it a key player in the European cancer biomarkers market. Early adoption of precision medicine and strong genomic research initiatives drive its growth. |
| 4 | China | US$ XX.X Mn | XX.X% | China represents a rapidly expanding market due to its immense patient population, rising healthcare expenditure, and significant government backing for biotech innovation and precision medicine initiatives. Domestic companies are rapidly developing and adopting advanced biomarker technologies. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia is heavily investing in upgrading its healthcare infrastructure and adopting advanced medical technologies, including precision oncology and cancer biomarkers. A high prevalence of certain cancers further drives the demand for innovative diagnostic solutions. |
Countries Covered (25)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Exact Sciences | XX.X% | Expand market share in early cancer detection and precision oncology through highly accurate diagnostic tests and a comprehensive portfolio. | — | — | CologuardOncotype DXOncotype MAP+1 |
| 2 | Guardant Health | XX.X% | Dominate the liquid biopsy market for advanced cancer treatment selection, recurrence monitoring, and early detection. | — | — | Guardant360Guardant RevealGuardant Health AMEA+1 |
| 3 | Natera | XX.X% | Leverage its personalized molecular residual disease (MRD) testing platform, Signatera, to become a standard of care for cancer recurrence monitoring. | — | — | SignateraPanoramaProspera+1 |
| 4 | Caris Life Sciences | XX.X% | Provide comprehensive molecular profiling and artificial intelligence-driven insights to guide precision cancer therapy for patients and drug development. | — | — | Caris Molecular IntelligenceCaris MI ExomeCaris MI Transcriptome+1 |
| 5 | Tempus | XX.X% | Build the world's largest library of clinical and molecular data to power precision medicine and accelerate drug discovery. | — | — | Tempus xTTempus xETempus xR+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, Qiagen, Myriad Genetics, Veracyte, NeoGenomics, Adaptive Biotechnologies, Freenome, Personalis, Biodesix, MDxHealth, Burning Rock Biotech, Epigenomics AG, Oncocyte, Angle plc, VolitionRx, DiaCarta
The global Cancer Biomarkers market features a competitive landscape led by Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, and Qiagen, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Exact Sciences
Guardant Health
Natera
Caris Life Sciences
Tempus
Qiagen
Myriad Genetics
Veracyte
NeoGenomics
Adaptive Biotechnologies
Freenome
Personalis
Biodesix
MDxHealth
Burning Rock Biotech
Epigenomics AG
Oncocyte
Angle plc
VolitionRx
DiaCarta
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Guardant Health Launches Enhanced Liquid Biopsy for Early Cancer Detection
Guardant Health announced the commercial launch of its new multi-cancer early detection liquid biopsy test, offering improved sensitivity and specificity across various solid tumors. This expands access to non-invasive screening methods for a broader patient population.
Roche Acquires AI-Driven Biomarker Discovery Firm 'BioPredict Solutions'
Roche Diagnostics completed the acquisition of BioPredict Solutions, a startup specializing in AI-driven biomarker discovery and validation for immuno-oncology. This strategic move aims to bolster Roche's precision medicine pipeline and accelerate the identification of novel therapeutic targets.
Eli Lilly Forms Strategic Alliance with Illumina for Companion Diagnostics
Eli Lilly and Illumina entered a multi-year partnership to develop companion diagnostic tests for Lilly's pipeline of oncology therapeutics. The collaboration will leverage Illumina's next-generation sequencing platforms to identify predictive biomarkers, enhancing treatment personalization.
GRAIL Secures US$ XX.X in Funding to Advance Multi-Cancer Early Detection Research
GRAIL, a leader in multi-cancer early detection, announced a significant new funding round of US$ XX.X to accelerate clinical trials and expand its research and development capabilities for next-generation biomarker platforms. This investment underscores confidence in the future of liquid biopsy technologies.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $25.0 Bn |
| Market Size (Forecast) | $64.8 Bn |
| CAGR | 10.0% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 25 Countries |
| Segments Covered | 6 Segments, 37 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Cancer Biomarkers Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Cancer Biomarkers Market is estimated at $25.0 Bn in 2025. It is forecast to reach $64.8 Bn in 2035, indicating substantial growth over the decade.
The Cancer Biomarkers Market is forecast to grow at a CAGR of 10.0% from 2025 to 2035. This growth is driven by increasing cancer incidence and advancements in personalized medicine.
The market is segmented by Type, Application, Technology, Cancer Type, End-User, and Source. Key types include Protein Biomarkers and Genetic & Genomic Biomarkers, while applications cover Diagnosis, Prognosis, and Theragnostics & Treatment Selection.
Leading companies in the Cancer Biomarkers market include Exact Sciences, Guardant Health, Natera, Caris Life Sciences, Tempus, Qiagen, Myriad Genetics, Veracyte, NeoGenomics, Adaptive Biotechnologies, Freenome, and Personalis.
The report covers market sizing and forecasts from 2025 to 2035, global market coverage across major regions, and analysis of diagnostic, prognostic, and predictive biomarker applications in oncology. It provides a detailed breakdown of market segments and competitive landscape.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Cancer Genomics Market
$18.9 Bn in 2025 · 12.1% CAGR
Cancer Immunotherapy Market
$228.6 Bn in 2025 · 9.0% CAGR
Neurology Biomarkers Market
$2.4 Bn in 2025 · 13.1% CAGR
Personalized Cancer Vaccines Market
$416.0 Mn in 2025 · 29.0% CAGR
Companion Diagnostics Market
$8.1 Bn in 2025 · 18.8% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR
Advanced Drug Delivery Systems Market
$68.5 Bn in 2025 · 15.4% CAGR
AI Bioengineering Market
$2.7 Bn in 2025 · 25.5% CAGR